Literature DB >> 15882217

Efficacy of a 0.15% benzydamine hydrochloride and 0.05% cetylpyridinium chloride mouth rinse on 4-day de novo plaque formation.

David Herrera1, Sagrario Santos, Jorge Ferrús, Germán Barbieri, Leonardo Trombelli, Mariano Sanz.   

Abstract

OBJECTIVE: To evaluate the effect of a mouth-rinse formulation combining benzydamine hydrochloride and cetylpyridinium chloride (BNZ+CPC) in preventing de novo plaque formation, in comparison with CPC and placebo mouth rinses. PATIENTS AND METHODS: This was a controlled, observer-blind, cross-over study. In this model of plaque re-growth, subjects received a session of oral prophylaxis and were directed to withdraw oral hygiene measures for the next 4 days, using only the mouth rinse assigned. The outcome parameters were the plaque index (PlI) and gingival index (GI). In addition, microbiological evaluation of the subgingival microflora, by means of culture, was performed, as well as patient-based variables. Data analysis was carried out using anova for Latin-square design.
RESULTS: The analysis of variance showed a significant statistical difference between the BNZ+CPC association and placebo (p<0.0001). No differences between CPC and placebo were detected considering multiple comparisons between treatments. The 90% confidence interval of the differences between BNZ+CPC and CPC showed no equivalence between treatments, being the PlI lower in the BNZ+CPC group. No significant difference between groups in GI was observed. Mean anaerobic colony-forming units (CFU) demonstrated a significant increase between visits in all groups (p<0.001) and differences among groups were not significant. Subjects treated with BNZ+CPC frequently reported "tingling mouth" and "numbness mouth".
CONCLUSION: Within the limitations of the study model, the BNZ+CPC combination showed a statistically significant plaque-inhibitory capacity, as compared with the placebo mouth rinse, and an additive effect as compared with CPC. No relevant clinical or microbiological adverse effects were detected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882217     DOI: 10.1111/j.1600-051X.2005.00718.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  6 in total

1.  Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system.

Authors:  Jabar A Faraj; Rossella Dorati; Aurélie Schoubben; David Worthen; Francesca Selmin; Yilmaz Capan; Kai Leung; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2007-03-30       Impact factor: 3.246

2.  Heat shock protein 90 inhibitors repurposed against Entamoeba histolytica.

Authors:  Dea Shahinas; Anjan Debnath; Christan Benedict; James H McKerrow; Dylan R Pillai
Journal:  Front Microbiol       Date:  2015-04-28       Impact factor: 5.640

Review 3.  Adverse events associated with home use of mouthrinses: a systematic review.

Authors:  Gianluca M Tartaglia; Santosh Kumar Tadakamadla; Stephen Thaddeus Connelly; Chiarella Sforza; Conchita Martín
Journal:  Ther Adv Drug Saf       Date:  2019-09-23

4.  Comparative in vitro evaluation of the antimicrobial activities of povidone-iodine and other commercially available antiseptics against clinically relevant pathogens.

Authors:  Eng Lee Tan; Nur Humaira Johari
Journal:  GMS Hyg Infect Control       Date:  2021-01-26

5.  Antiplaque and antigingivitis effects of a mouthrinse containing cetylpyridinium chloride, triclosan and dipotassium glycyrrhizinate.

Authors:  Jae-Yong Shim; Sung-Bin Yim; Jin-Hyung Chung; Ki Seok Hong
Journal:  J Periodontal Implant Sci       Date:  2012-04-30       Impact factor: 2.614

6.  Effects of benzydamine and mouthwashes containing benzydamine on Candida albicans adhesion, biofilm formation, regrowth, and persistence.

Authors:  Andrea Ardizzoni; Giorgia Boaretto; Eva Pericolini; Diego Pinetti; Alessandra Capezzone de Joannon; Lucia Durando; Lorella Ragni; Elisabetta Blasi
Journal:  Clin Oral Investig       Date:  2022-01-23       Impact factor: 3.573

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.